# US 2023/0053563 A1 · Novel il2 agonists and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053563 A1
- Document ID: US20230053563A1
- Status: Published application
- Kind: A1
- Application number: 17/843,157
- Filed: 2022-06-17
- Published: 2023-02-23
- Earliest claimed: 2019-12-20
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Jiaxi WU; Tong ZHANG; Maria del Pilar MOLINA-PORTELA; Eric Smith; Chia-Yang LIN; Thomas Craig Meagher
- Web page: https://patentgrep.com/patent/US20230053563A1

## CPC

- C07K 14/55: IL-2
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/2013: {IL-2}
- A61K 39/0011: {Cancer antigens}
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4234: {Interleukins [IL]}
- A61K 40/46: Viral antigens
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/5443: {IL-15}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2818: {against CD28 or CD152}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2239/50: Colon
- A61K 2239/55: Lung
- A61K 2239/57: Skin; melanoma
- C07K 16/084: Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/13034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to IL2 agonists with improved therapeutic profiles.

## Claims

### Claim 1

An IL2 agonist comprising:
(a) an Fc domain; an
(b) an IL2 moiety C-terminal to the Fc domain, wherein the IL2 moiety comprises an IL2 domain and an IL2-Rα domain.

### Claim 2 (depends on 1)

The IL2 agonist of claim 1, wherein the IL2 domain is N-terminal to the IL2-Rα domain.

### Claim 3 (depends on 1)

The IL2 agonist of claim 1, wherein the IL2 domain is C-terminal to the IL2-Rα domain.

### Claim 4 (depends on 1, 2, 3)

The IL2 agonist of any one of claims 1 to 3, wherein the IL2 moiety comprises an IL2 domain comprising an amino acid sequence having:
(a) at least about 90% or at least about 95% sequence identity to mature human IL2,
(b) an N-terminal alanine deletion as compared to mature human IL2;
(c) an IL2 variant which has an amino acid substitution at position N88 as compared to wild type IL2, optionally wherein the amino acid substitution is N88D;
(d) the amino acid substitution C125S, C125A or C125V as compared to wild type IL2; or
(e) any combination of (a), (b), (c) and/or (d).

### Claim 5 (depends on 1, 2, 3, 4)

The IL2 agonist of any one of claims 1 to 4, wherein the IL2-Rα domain comprises or consists of an amino acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or 100% sequence identity to an IL2 binding portion of human IL-2Rα, optionally wherein said binding portion has:
(a) at least 160 amino acids, at least 161 amino acids, at least 162 amino acids, at least 164 amino acids or at least 165 amino acids of human IL2-Rα; and/or
(b) up to 251, up to 240, up to 230, up to 220, up to 210, up to 200, up to 190, up to 180 or up to 170 amino acids of the extracellular domain of human IL2-Rα.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The IL2 agonist of any one of claims 1 to 5, wherein the IL2 domain and the IL2-Ra domain are connected via a linker (“the IL2 moiety linker”).

### Claim 7 (depends on 6)

The IL2 agonist of claim 6, wherein the IL2 moiety linker is at least 10 or at least 15 amino acids in length.

### Claim 8 (depends on 6, 7)

The IL2 agonist of claim 6 or claim 7, wherein the IL2 moiety linker is or comprises a glycine-serine linker.

### Claim 9 (depends on 6, 7, 8)

The IL2 agonist of any one of claims 6 to 8, wherein the IL2 moiety linker comprises the amino acid sequence G4S (SEQ ID NO:57).

### Claim 10 (depends on 9)

The IL2 agonist of claim 9, wherein the IL2 moiety linker is or comprises a multimer of the amino acid sequence G4S (SEQ ID NO:57).

### Claim 11 (depends on 10)

The IL2 agonist of claim 10, wherein the multimer comprises 2, 3, 4, 5, 6 or more repeats of the amino acid sequence G4S (SEQ ID NO:57).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The IL2 agonist of any one of claims 1 to 11, wherein the Fc domain and the IL2 moiety are connected via a linker (the “Fc-IL2 linker”).

### Claim 13 (depends on 12)

The IL2 agonist of claim 12, wherein the Fc-IL2 linker is at least 5 or at least 10 amino acids in length.

### Claim 14 (depends on 12, 13)

The IL2 agonist of claim 12 or claim 13, wherein the Fc-IL2 linker is or comprises a glycine-serine linker.

### Claim 15 (depends on 12, 13, 14)

The IL2 agonist of any one of claims 12 to 14, wherein the Fc-IL2 linker comprises the amino acid sequence G4S (SEQ ID NO:57).

### Claim 16 (depends on 9)

The IL2 agonist of claim 9, wherein the Fc-IL2 linker is or comprises a multimer of the amino acid sequence G4S (SEQ ID NO:57).

### Claim 17 (depends on 10)

The IL2 agonist of claim 10, wherein the multimer comprises 2, 3, 4, 5, 6 or more repeats of the amino acid sequence G4S (SEQ ID NO:57).

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The IL2 agonist of any one of claims 1 to 17, wherein the Fc domain is an IgG1, IgG2, IgG3 or IgG4 Fc domain.

### Claim 19 (depends on 18)

The IL2 agonist of claim 18, wherein the Fc domain has reduced effector function.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The IL2 agonist of any one of claims 1 to 19 which is a dimer.

### Claim 21 (depends on 20)

The IL2 agonist of claim 20, which is a homodimer.

### Claim 22 (depends on 20)

The IL2 agonist of claim 20, which is a heterodimer.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The IL2 agonist of any one of claims 1 to 22, which is bivalent for the IL2 moiety.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The IL2 agonist of any one of claims 1 to 23, which comprises a targeting moiety.

### Claim 25 (depends on 24)

The IL2 agonist of claim 24, wherein the targeting moiety is N-terminal to the Fc domain.

### Claim 26 (depends on 24, 25)

The IL2 agonist of claim 24 or claim 25, wherein the targeting moiety:
(a) binds to a tumor associated antigen;
(b) binds to a tumor microenvironment antigen;
(c) binds to a cell surface molecule of tumor reactive lymphocytes;
(d) binds to a checkpoint inhibitor;
(e) binds to a peptide-MHC complex;
(f) is a peptide-MHC complex; or
(g) binds to an antigen associated with or targeted by an autoimmune response.

### Claim 27 (depends on 26)

The IL2 agonist of claim 26, wherein the targeting moiety binds to a tumor associated antigen.

### Claim 28 (depends on 27)

The IL2 agonist of claim 27, wherein the tumor associated antigen is Fibroblast Activation Protein (FAP), the A1 domain of Tenascin-C (TNC A1), the A2 domain of Tenascin-C (TNC A2), the Extra Domain B of Fibronectin (EDB), the Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), MART-1/Melan-A, gp100, Dipeptidyl peptidase IV (DPPIV), adenosine deaminase-binding protein (ADAbp), cyclophilin b, colorectal associated antigen (CRC)-C017-1A/GA733, Carcinoembryonic Antigen (CEA) and its immunogenic epitopes CAP-1 and CAP-2, etv6, aml1, Prostate Specific Antigen (PSA) or an immunogenic epitopes thereoPSA-1, PSA-2, and PSA-3, prostate-specific membrane antigen (PSMA), T-cell receptor/CD3-zeta chain, MAGE-family of tumor antigens (e.g., MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-Xp2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), MAGE-C1, MAGE-C2, MAGE-C3, MAGE-C4, MAGE-C5), GAGE-family of tumor antigens (e.g., GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, GAGE-9), BAGE, RAGE, LAGE-1, NAG, GnT-V, MUM-1, CDK4, tyrosinase, p53, MUC family, HER2/neu, p21ras, RCAS1, α-fetoprotein, E-cadherin, α-catenin, β-catenin and γ-catenin, p120ctn, gp100 Pmel117, PRAME, NY-ESO-1, cdc27, adenomatous polyposis coli protein (APC), fodrin, Connexin 37, Ig-idiotype, p15, gp75, GM2 and GD2 gangliosides, viral products such as human papilloma virus proteins, Smad family of tumor antigens, Imp-1, P1A, EBV-encoded nuclear antigen (EBNA)-1, brain glycogen phosphorylase, SSX-1, SSX-2 (HOM-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1 and CT-7, c-erbB-2, Her2, EGFR, IGF-1R, CD2 (T-cell surface antigen), CD3 (heteromultimer associated with the TCR), CD22 (B-cell receptor), CD23 (low binding affinity IgE receptor), CD30 (cytokine receptor), CD33 (myeloid cell surface antigen), CD40 (tumor necrosis factor receptor), IL-6R-(IL6 receptor), CD20, MCSP, PDGF βR (β-platelet-derived growth factor receptor), ErbB2 epithelial cell adhesion molecule (EpCAM), EGFR variant III (EGFRvIII), CD19, disialoganglioside GD2, ductal-epithelial mucine, gp36, TAG-72, glioma-associated antigen, β-human chorionic gonadotropin, alphafetoprotein (AFP), lectin-reactive AFP, thyroglobulin, MN-CA IX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxyl esterase, mut hsp70-2, M-CSF, prostase, prostase specific antigen (PSA), PAP, LAGA-1a, p53, prostein, PSMA, surviving and telomerase, prostate-carcinoma tumor antigen-1 (PCTA-1), ELF2M, neutrophil elastase, ephrin B2, insulin growth factor (IGF1)-I, IGF-II, IGFI receptor, 5T4, ROR1, Nkp30, NKG2D, tumor stromal antigens, the extra domain A (EDA) or extra domain B (EDB) of fibronectin, or the A1 domain of tenascin-C (TnC A1).

### Claim 29 (depends on 26, 27)

The IL2 agonist of claim 26 or claim 27, wherein the tumor associated antigen is a viral antigen.

### Claim 30 (depends on 29)

The IL2 agonist of claim 29, wherein the viral antigen is Epstein-Barr virus LMP-1, hepatitis C virus E2 glycoprotein, HIV gp160, or HIV gp120, HPV E6, HPV E7, CMV early membrane antigen (EMA) or CMV late membrane antigen (LMA).

### Claim 31 (depends on 26)

The IL2 agonist of claim 26, wherein the targeting moiety binds to a tumor microenvironment antigen.

### Claim 32 (depends on 31)

The IL2 agonist of claim 31, wherein the tumor microenvironment antigen is an extracellular matrix protein.

### Claim 33 (depends on 32)

The IL2 agonist of claim 32, wherein the extracellular matrix protein is syndecan, heparanase, integrins, osteopontin, link, cadherins, laminin, laminin type EGF, lectin, fibronectin, notch, tenascin, collagen and matrixin.

### Claim 34 (depends on 26)

The IL2 agonist of claim 26, wherein the targeting moiety binds to a cell surface molecule of tumor lymphocytes.

### Claim 35 (depends on 34)

The IL2 agonist of claim 34, wherein the cell surface molecule is CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, LAG3, TIM3, or B7-H3.

### Claim 36 (depends on 35)

The IL2 agonist of claim 35, wherein the cell surface molecule is PD1.

### Claim 37 (depends on 36)

The IL2 agonist of claim 36, wherein targeting moiety is an anti-PD1 antibody or antigen binding fragment thereof.

### Claim 38 (depends on 35)

The IL2 agonist of claim 35, wherein the cell surface molecule is LAG3.

### Claim 39 (depends on 26)

The IL2 agonist of claim 26, wherein the targeting moiety binds to a checkpoint inhibitor.

### Claim 40 (depends on 39)

The IL2 agonist of claim 39, wherein the checkpoint inhibitor is CTLA-4, PD1, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, VISTA, PSGL1, or CHK2.

### Claim 41 (depends on 40)

The IL2 agonist of claim 40, wherein the checkpoint inhibitor is PD1.

### Claim 42 (depends on 40)

The IL2 agonist of claim 40, wherein the checkpoint inhibitor is LAG3.

### Claim 43 (depends on 41)

The IL2 agonist of claim 41, wherein the targeting moiety binds to an MHC-peptide complex.

### Claim 44 (depends on 43)

The IL2 agonist of claim 43 wherein the peptide in the peptide-MHC complex comprises a tumor neoantigen.

### Claim 45 (depends on 44)

The IL2 agonist of claim 44, wherein the tumor neoantigen is LCMV derived peptide gp33-41, APF (126-134), BALF (276-284), CEA (571-579), CMV pp65 (495-503), FLU-M1 (58-66), gp100 (154-162), gp100 (209-217), HBV Core (18-27), Her2/neu (369-377;V2v9); HPV E7 (11-20), HPV E7 (11-19), HPV E7 (82-90), KLK4 (11-19), LMP1 (125-133), MAG-A3 (112-120), NYESO1 (157-165, C165A), NYESO1 (157-165, C165V), p54 WT (264-272), PAP-3 (136-143), PSMA (4-12), PSMA (135-145), Survivin (96-014), Tyrosinase (369-377, 371D), or WT1 (126-134).

### Claim 46 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The IL2 agonist of any one of claims 26 to 45, wherein the targeting moiety is an antibody or antigen binding fragment thereof.

### Claim 47 (depends on 46)

The IL2 agonist of claim 46, wherein the targeting moiety is a Fab.

### Claim 48 (depends on 46)

The IL2 agonist of claim 46, wherein the targeting moiety is a scFv.

### Claim 49 (depends on 26)

The IL2 agonist of claim 26, wherein the targeting moiety is a peptide-MHC complex.

### Claim 50 (depends on 49)

The IL2 agonist of claim 49, wherein the peptide-MHC complex binds to the T cell receptor of tumor lymphocytes.

### Claim 51 (depends on 49, 50)

The IL2 agonist of claim 49 or claim 50, wherein the peptide in the peptide-MHC complex comprises a tumor neoantigen.

### Claim 52 (depends on 51)

The IL2 agonist of claim 51, wherein the tumor neoantigen is LCMV derived peptide gp33-41, APF (126-134), BALF (276-284), CEA (571-579), CMV pp65 (495-503), FLU-M1 (58-66), gp100 (154-162), gp100 (209-217), HBV Core (18-27), Her2/neu (369-377;V2v9); HPV E7 (11-20), HPV E7 (11-19), HPV E7 (82-90), KLK4 (11-19), LMP1 (125-133), MAG-A3 (112-120), NYESO1 (157-165, C165A), NYESO1 (157-165, C165V), p54 WT (264-272), PAP-3 (136-143), PSMA (4-12), PSMA (135-145), Survivin (96-014), Tyrosinase (369-377, 371D), or WT1 (126-134).

### Claim 53 (depends on 49)

The IL2 agonist of claim 49, wherein the peptide in peptide-MHC complex comprises a viral antigen.

### Claim 54 (depends on 53)

The IL2 agonist of claim 53, wherein the viral antigen is CMVpp65 or HPV16E7.

### Claim 55 (depends on 49, 50, 51, 52, 53, 54)

The IL2 agonist of any one of claims 49 to 54, wherein the peptide-MHC complex further comprises β2 microglobulin or a fragment thereof.

### Claim 56 (depends on 55)

The IL2 agonist of claim 55, wherein the peptide MHC complex comprises a type I MHC domain.

### Claim 57 (depends on 56)

The IL2 agonist of claim 56, wherein the peptide MHC complex comprises, in an N- to C-terminal orientation a MHC peptide, a linker, a β2-microglobulin domain, a linker, and a type I MHC domain.

### Claim 58 (depends on 57)

The IL2 agonist of claim 57, wherein the linker connecting the MHC peptide and the β2-microglobulin domain comprises the amino acid sequence GCGGS.

### Claim 59 (depends on 49, 50, 51, 52, 53, 54)

The IL2 agonist of any one of claim 49 to 54, wherein the peptide-MHC complex does not comprise β2 microglobulin or a fragment thereof.

### Claim 60 (depends on 59)

The IL2 agonist of claim 59, wherein the peptide MHC complex comprises a type II MHC domain.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

A nucleic acid or plurality of nucleic acids encoding the IL2 agonist of any one of claims 1 to 60.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

A host cell engineered to express the IL2 agonist of any one of claims 1 to 60 or the nucleic acid(s) of claim 61.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62)

A method of producing the IL2 agonist of any one of claims 1 to 60, comprising culturing the host cell of claim 62 and recovering the IL2 agonist expressed thereby.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

A pharmaceutical composition comprising the IL2 agonist of any one of claims 1 to 60 and an excipient.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 64)

A method of treating cancer, comprising administering to a subject in need thereof the IL2 agonist of any one of claims 1 to 60 or the pharmaceutical composition of claim 64.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of treating cancer, comprising administering to a subject in need thereof:
(a) chimeric antigen receptor (“CAR”) T cells (“CART cells”); and
(b) an IL2 agonist according to any one of claims 1 to 26 comprising a targeting moiety that binds to the T cell receptor of the CART cells or another cell surface molecule on the CART cells, optionally wherein the targeting moiety is capable of binding to the extracellular domain of the CAR.

### Claim 67 (depends on 65, 66)

The method of claim 65 or claim 66, which further comprises administering an anti-PD1 antibody to the subject.

### Claim 68 (depends on 67)

The method of claim 67, wherein the anti-PD1 antibody is MDX-1106 (nivolumab), MK-3475 (pembrolizumab), MEDI-0680 (AMP-514), PDR001, REGN2810, or BGB-108.
